Streetwise Reports' Article Archives — September 2019 back to current month (131)
The latest clinical trial results are dissected in a ROTH Capital Partners report.
These agreements come after Mercedes-Benz ended its arrangement with the small-cap.
The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report.
Money manager Adrian Day reviews two undervalued resource companies that have seen important recent developments.
The transaction yielded for the company $30 million in cash, a production royalty and event-specific revenue.
Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share.
The Critical Investor reviews Golden Arrow's deal with SSR Mining to sell its remaining interest, and also discusses the company's other projects.
The result reportedly shows the potential of the formation within a specific block.
My Second-Worst Nightmare (09/30/2019)
Sector expert Michael Ballanger interprets the implications of the last COT report for the precious metals markets.
Company notes "significant increases in gold grade and ounces of gold."
Next for the Canadian company and its asset is updating the mineral resource estimate.
The drill results and next steps are reviewed in a Mackie Research Capital Corp. report.
The developer of this system continues to sign collaboration agreements.
Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer.
Mineral Exploration Company Provides Project Updates (09/26/2019)
At its latest-stage asset, the firm continues to advance the recognized potential for development of bulk-tonnage, polymetallic deposits.
In this interview with Maurice Jackson of Proven and Probable, Aben Resources' CEO explores the ramifications of recent analytical results from the company's flagship project.
The company's proprietary technology lowers costs and makes it scalable.
Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint.
In a report, iA Securities explains the deal and makes a recommendation to the shareholders of the seller.
The Canadian company continues to unlock the discovery potential there.
The synergies, potential and realized, that resulted from combining these two companies' Nevada assets are discussed in a BMO Capital Markets report.
The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hypercholesterolemia, which leads to high levels of LDL-C, and one for atherosclerotic cardiovascular disease.
Blackrock Swings for the Fences for Gold in Nevada (09/25/2019)
Bob Moriarty of 321 Gold explains why he's a fan of this company's exploration efforts.
The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects.
The change went into effect today.
That stage will include system integration and product testing.
The mineralization there represents ounces that could be added to the existing resources.
Total proceeds equal about CA$0.74 per outstanding common share of the company.
The Critical Investor delves into this lithium firm's recovery method for its Arkansas project and why it may succeed when other companies' have not.
This new official status should benefit the company in numerous ways.
High grades and a new envelope of mineralization are among the results.
The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report.
Maurice Jackson of Proven and Probable interviews the CEO of this project generator about the prospects for its latest acquisition.
It allows anyone to upload and use a three-dimensional model as an AR object online.
The intercept, which encounters copper association at depth, extends the mineralized zone.
Something Wicked This Way Comes (09/24/2019)
Precious metals expert Michael Ballanger dissects the recent Federal Reserve injection of liquidity into the market and contemplates what could be behind it.
Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies.
Technical analyst Clive Maund charts this copper and gold stock that is exploring a project in British Columbia that he rates an "immediate buy."
Assays and resource forecasts pertaining to this silver project in Bolivia are discussed in a ROTH Capital Partners report.
Key points from the miner's company update at the Denver Gold Forum are summarized in a CIBC report.
Peter Epstein of Epstein Research speaks with Peter Leaman, SVP exploration of Kincora Copper, after the company released the first of its drill results.
Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019.
A Pareto Securities report addresses how the various joint venture wells of the firm derisk potential upside to its share price.
The Canadian company intends to develop a game-changing mass medium.
Cannabis Company Expands Operations with New Plant (09/20/2019)
The firm will use this second manufacturing facility only for making reagents.
With this program, the Canadian firm entered the New England energy market.
With these new contracts, the Vancouver-based company continues to build its momentum in Texas.
In this interview with Craig Taylor, CEO of Defense Metals Corp., Peter Epstein of Epstein Research delves into the complexities and potential of rare earth metals markets, and discusses the company's REE projects.
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication.
The findings are presented and discussed in a BMO Capital Markets report.
The key points regarding recent drill results and next steps are presented in a Haywood report.
The support of the Puerto Rico Financial Oversight and Management Board advances the solar project.
The agricultural market represents a tremendous opportunity for this firm's technology.
Two joint venture projects, this one and another in Indonesia, continue moving forward.
By applying its technology, the former will enhance the latter's recruitment materials.
With recent results, the Canadian company expanded its gold-silver-copper footprint in a single zone at the property.
Bill Powers of Mining Stock Education interviewed Greg Crowe, president and CEO of Silver One Resources, at the recent Beaver Creek Precious Metals Summit, and got an overview of the company's two Nevada silver projects and their potential upside for investors.
SunPower Corp. shares are trading 6% higher today as the firm announced that its Equinox Storage paired with its platform provides energy independence to residential users.
Gold Leads, Will the Rest Follow? (09/19/2019)
Fund manager Matt Geiger provides his overview of the resource market and shares some principles he is using to invest in today's market.
FedEx Corp. shares are trading much lower today after it reported Q1/20 earnings. The firm confirmed it will raise prices by 4.9% to 5.9% in January 2020.
These results are from the recently completed clinical trial of the firm's lead drug candidate.
The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report.
The reasons to be optimistic about this company are covered in a BMO Capital Markets report.
Most recent exploration work, specifically a drill program, was done there between 2005 and 2007.
The mine complex is producing ore, but it is being stockpiled until state requirements are met.
Firm Enhances Imaging Improvement Product (09/17/2019)
With the upgrades, the technology can now be deployed in smaller cameras.
The new arrangement will go into effect at the end of this month.
Property receives first drilling in more than a decade.
Shares of Apogee Enterprises are trading higher today after the commercial and architectural glass and framing company announced Q2/20 earnings and updated its estimates for the rest of the year.
Israel Made the Attack on the Saudi Oil Fields (09/16/2019)
Bob Moriarty posits his theories on the attack on Saudi oil refinery.
Idaho Gold Developer Demonstrates Post-Tax 53% IRR (09/16/2019)
Bill Powers of the Mining Stock Education podcast discusses the news flow from this junior explorer.
Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion.
This logistics service should begin in Calgary in around a month.
This newly found mineralized zone remains open in all directions.
Global Insanity Prevails (09/14/2019)
Sector expert Michael Ballanger uses storytelling and personal experience to unpack the myths and machinations behind the precious metals and financial markets.
The new report incorporates metallurgical, design and schedule changes.
This is one way the Canadian firm is providing convenient, patient-centric service.
Sports and entertainment venues is one of this security technology company's key market verticals.
Drone Delivery Canada Opens Operations Center (09/13/2019)
Recent developments for this firm, including the announcement of its first commercial customer, examined by Peter Epstein of Epstein Research.
Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share.
Gold Weather Veins in Big Red (09/12/2019)
The explorer recently released early-stage sampling results for its Golden Triangle property that identifies a "significant gold discovery."
Shares of Moderna Inc. traded up double-digits as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus.
Bob Moriarty of 321 Gold discusses what the Daily Sentiment Indicator is saying about the precious metals markets.
Key points management made on a recent investor tour are presented in a BMO Capital Markets report.
This proprietary method ensures the firm meets the requirements for its cannabis-containing beverages and oils.
Opportunities exist for expansion beyond the base case scenario.
The company will provide threat detection and counter-terrorism solutions at this first-of-its-kind project in the world.
The company already began exploration work there with the goal of defining drill targets.
The firm shipped a record amount to that state in August.
The highlights of the U.S. firm and its product are presented in a Laurentian Bank Securities report.
Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista.
The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report.
This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million.
The small-cap energy storage firm just signed a global production agreement with industry heavyweight Jabil.
Condolences on the Death of Barbara Moriarty (09/10/2019)
We are deeply saddened to hear of the death of Barbara Moriarty, cofounder of 321 Gold.
Shares of Mallinckrodt Plc are trading more than 60% higher today on news that the company is selling its CDMO subsidiary BioVectra Inc. to H.I.G. Capital for $250 million.
Red Lake Explorer Keeps Making Discoveries (09/10/2019)
Chris Taylor, CEO of Great Bear Resources, talks with Maurice Jackson of Proven and Probable about his company's exploration efforts in Canada's prolific Red Lake District.
This is the first organization of its kind to collaborate in this regard.
Wounded Animals, Indeed (09/09/2019)
Sector expert Michael Ballanger offers his observations of recent activity in the gold and silver markets.
Silver's Sharp Reaction Back (09/09/2019)
Technical analyst Clive Maund charts silver and explains why he believes it hasn't hit a final top.
Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint.
Technical analyst Clive Maund discusses the factors he sees pulling gold down.
This is the first of many such potential payments under the related agreement.
This move is a key differentiator for future development of the Canadian company's platform.
This asset is another significant addition to the firm's expanding portfolio.
Exploring for Copper in Major Belt in the Yukon (09/09/2019)
Tim Johnson, CEO of Granite Creek Copper, speaks with Maurice Jackson of Proven and Probable about his company's exploration activities in the Yukon.
This company's unique option/royalty model has caught the attention of major resource investors.
The revisions and the reasons for them are discussed in a ROTH Capital Partners report.
The reasons this energy firm warrants a rerating are discussed in a Raymond James report.
The recently released resource estimate and other reasons why this Canadian firm makes a premium takeout target are provided in an iA Securities report.
After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, but has since pulled back greatly.
Silver, Gold and Platinum Are Due a Break (09/05/2019)
Bob Moriarty of 321 Gold explains what one indicator is showing for the precious metals.
An agreement with Glencore enabling advancement of recommissioning and expansion plans for the junior's cobalt refinery makes First Cobalt a good bet for investors, according to Peter Epstein of Epstein Research.
Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease.
Coverage Initiated on 'Biotech Machine' (09/04/2019)
The compelling reasons behind those descriptors are explored in a Dawson James Securities report.
The study data and their implications are provided in a BTIG report.
The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report.
The company calls its first month of reconnaissance drilling along the LP Fault "highly successful."
The company makes this move after building out its distribution and dealer network.
The Vancouver-based explorer has the second half of its planned drill campaign there yet to go.
Peter Epstein of Epstein Research outlines the latest from this firm operating in Nevada, which is set to release a PFS in the fourth quarter.
Coupa Software Shares Rise 10% on Q2 Earnings (09/04/2019)
Enterprise cloud software firm Coupa Software's shares are trading 10% higher today after the company announced Q2/20 earnings and issued a cautious macroeconomic outlook for the rest of 2019.
Investment Contrarians: To Be or Not To Be (09/04/2019)
Sector expert Michael Ballanger shares his dilemma in the face of a precious metals bull market.
Solid Growth with Innovation at Global Leader (09/04/2019)
Fund manager Adrian Day discusses developments at several global companies in his portfolio, including one that is performing very well and another that is hit on all sides.
To achieve this end, the company will work with a standardizing open industry forum.
The Great Precious Metals Melt-Up (09/03/2019)
Technical analyst Clive Maund presents his dystopian view of the future.
Fund manager Adrian Day discusses dividends and discounts among several non-resource companies in his portfolio.
Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases.
Firm Closes Purchase of Prospective Nevada Property (09/02/2019)
The transaction enhances the company's existing nearby project, where maiden drilling recently started.
Assay results are in from a high-priority target on the property.
Explorer Launches 360° Tour of Abitibi Gold Project (09/02/2019)
The new visual features allow investors to get a better understanding of the project and the existing drill results.
|"LIO's current valuation is an attractive entry point for investment."|
|"We are initiating coverage on ELY with an Outperform rating."|
|"NRG advanced its exploration program at Pamlico."|
|"PVG's revised Brucejack estimates leave room for outperformance."|
|"MAG is a good vehicle for exposure to the lesser precious metal."|